Skip to content

A randomized controlled study evaluating the efficacy of umbilical cord blood mononuclear cells in the treatment of children (aged 2-7 years) with cerebral palsy

A randomized controlled study evaluating the efficacy of umbilical cord blood mononuclear cells in the treatment of children (aged 2-7 years) with cerebral palsy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060455
Enrollment
Unknown
Registered
2022-06-01
Start date
2022-05-23
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy

Interventions

Experimental group:Umbilical cord blood mononuclear cells were transfused

Sponsors

The Second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 7 Years

Inclusion criteria

Inclusion criteria: 1. Children with cerebral palsy (spastic cerebral palsy caused by periventricular white matter injury, perinatal stroke or neonatal brain injury caused by intraventricular hemorrhage). 2. Meet Gross Motor Function Classification Score level(GMFCS) II-V. 3. Aged 2 to 7 years, weight 11-27kg, no gender limit. 4. Agreed to undergo post-rehabilitation treatment in the Second Hospital of Hebei Medical University.

Exclusion criteria

Exclusion criteria: 1. Existing history: intractable epilepsy, traumatic brain injury, hereditary disease, severe heart, lung, liver, and renal dysfunction (serum creatinine > 1.5 mg/dl, SGPT > 150 U/L at screening). History of syphilis, HIV and hepatitis; HIV+, immunosuppression (WBC 37.5?), vomiting, diarrhea, wheezing or wet rales. 4. Degenerative nervous system diseases (e.g., Batten disease, leukodystrophy, metabolic disorders, mitochondrial disorders, neurotransmitter disorders). 5. Microcephaly, macrocephaly, cortical malformation, genetic disorders of dysplastic encephalopathy caused by infection or metabolic diseases. 6. Previous history of stem cell therapy. 7. Patients who cannot cooperate with follow-up visits.

Design outcomes

Primary

MeasureTime frame
Activity of Daily Living (ADL) Score;Modified Ashworth Spasm Rating Scale;Pediatric Cerebral Palsy Gross Motor Assessment Scale Score;Comprehensive Functional Assessment Table of Cerebral Palsy;Language and Social Skills Tests;

Countries

China

Contacts

Public ContactWang Xiuxia

The Second Hospital of Hebei Medical University

wangxiuxia868@163.com+86 15803210573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026